Effects Of Atorvastatin On Macrophage Activity And Plaque Inflammation Using Magnetic Resonance Imaging

Condition(s) targeted: Atherosclerotic Disease, Carotid; Atheroma

Intervention: atorvastatin (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, MBBS MRCP, Study Director, Affiliation: GlaxoSmithKline

A new way of scanning narrowing in the arteries (main blood vessels) caused by fatty deposits known as plaques has been developed. Heart attacks and strokes occur when plaques become inflamed, depending on the artery affected. Currently used clinical tests can only tell us how much the vessel is blocked by the plaque and not how inflamed (i. e. dangerous) it is. This new method of scanning using magnetic resonance imaging (MRI) and a special agent called Sinerim can identify inflamed plaques. This study will evaluate patients with plaques in their arteries in their neck at risk of strokes to see whether treatment with a cholesterol-lowering drug called atorvastatin can reduce the amount of inflammation within the artery wall within the first three months of treatment. If this effect can be measured using MRI scanning with the use of Sinerim then the results of this study will provide additional clinical validation of the use of MRI scanning combined with agents such as Sinerem®.

Official title: A 12 Week, Randomised, Double Blind Study Evaluating the Effects of Low Dose (10mg) and High Dose (80mg) Atorvastatin on Macrophage Activity and Carotid Plaque Inflammation as Determined by Ultra Small Super-Paramagnetic Iron Oxide (USPIO) Enhanced Carotid Magnetic Resonance Imaging (MRI)

Study design: Treatment, Randomized, Double-Blind, Dose Comparison, Parallel Assignment, Efficacy Study

Primary outcome: Changes from baseline in USPIO-enhanced MRI signal in carotid plaques at 6 weeks and 12-weeks in low and high dose atorvastatin groups (within groups’ comparison).

Secondary outcome: Baseline corrected changes in USPIO-enhanced MRI signal in carotid plaques.Changes from baseline in tensile stress, micro-emboli counts, soluble plasma biomarkers at 12 weeks in low and high dose atorvastatin groups.

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion criteria: Positive Sinerem®-enhanced MRI of carotid plaque confirmed by a consultant neuroradiologist Must either be statin naive or have been on a stable dose of a statin(Permitted statins and total daily dose are as follows: atorvastatin =10mg, simvastatin =40mg, pravastatin =40mg, fluvastatin =80mg, rosuvastatin =10mg for =4 weeks prior to screening, with no evidence of statin intolerability.) Exclusion criteria: Require continued use of non-statin lipid modifying therapies or therapy with any other lipid regulating medications History of statin intolerance History of chronic viral hepatitis or other liver dysfunction Renal impairment with serum creatinine >2. 5 mg/dl (>221 mol/L) History of myopathy or inflammatory muscle disease, or 3 times more than the upper limit of normal levels of total creatinine kinase in serum Doppler assessment of less than 40% stenosis during screening assessment Allergy to dextran and iron salts Contraindication to MRI scanning Planned carotid surgery or endovascular intervention earlier than 10 weeks within the study period

GSK Clinical Trials Call Centre, Cambridge CB2 2GG, United Kingdom; Recruiting
GSK Clinical Trial Call Centre, Phone: 1-877-379-3718

Starting date: July 2006
Last updated: April 16, 2007